We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Guggulipid for the Treatment of Hypercholesterolemia: A Randomized Controlled Trial.
- Authors
Szapary, Philippe O.; Wolfe, Megan L.; Bloedon, LeAnne T.; Cucchiara, Andrew J.; DerMarderosian, Ara H.; Cirigliano, Michael D.; Rader, Daniel J.
- Abstract
Context: Herbal extracts from Commiphora mukul (guggul) have been widely used in Asia as cholesterol-lowering agents, and their popularity is increasing in the United States. Recently, guggulsterones, the purported bioactive compounds of guggul, have been shown to be potent antagonists of 2 nuclear hormone receptors involved in cholesterol metabolism, establishing a plausible mechanism of action for the hypolipidemic effects of these extracts. However, there are currently no published safety or efficacy data on the use of guggul extracts in Western populations. Objective: To study the short-term safety and efficacy of 2 doses of a standardized guggul extract (guggulipid, containing 2.5% guggulsterones) in healthy adults with hyperlipidemia eating a typical Western diet. Design: Double-blind, randomized, placebo-controlled trial using a parallel design, conducted March 2000-August 2001. Participants and Setting: A total of 103 ambulatory, community-dwelling, healthy adults with hypercholesterolemia in the Philadelphia, Pa, metropolitan area. Intervention: Oral, 3 times daily doses of standard-dose guggulipid (1000 mg), high-dose guggulipid (2000 mg), or matching placebo. Main Outcome Measures: Percentage change in levels of directly measured low-density lipoprotein cholesterol (LDL-C) after 8 weeks of therapy. Secondary outcome measures included levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and directly measured very low-density lipoprotein cholesterol (VLDL-C), as well as adverse events reports and laboratory safety measures including electrolyte levels and hepatic and renal function. Results: Compared with participants randomized to placebo (n = 36), in whom levels of LDL-C decreased by 5%, both standard-dose guggulipid (n = 33) and high-dose guggulipid (n = 34) raised levels of LDL-C by 4% (P = .01 vs placebo) and 5% (P = .006 vs placebo), respectively, at 8 weeks, for a net positive change of 9% to 10%. There were no...
- Subjects
COMMIPHORA wightii; CHOLESTEROL; HYPERLIPIDEMIA; PLACEBOS
- Publication
JAMA: Journal of the American Medical Association, 2003, Vol 290, Issue 6, p765
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.290.6.765